Targacept to Present at the Stifel Healthcare Conference 2013
WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept, Inc. (TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel Boston on Thursday, September 12, 2013 at 8:35 a.m. Eastern Time.
The presentation will be webcast and accessible from the Investor Relations page of Targacepts website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Investor Calendar section of the Investor Relations page of Targacepts website for at least two weeks following the event.
Targacept is developing an advanced clinical pipeline of NNR Therapeutics" to treat patients suffering from serious nervous system and gastrointestinal/genitourinary diseases and disorders. Many diseases arise from abnormalities in signaling within and between the brain and other organ systems such as the bladder and the GI tract. Targacepts NNR Therapeutics have the potential to normalize these signaling pathways to provide significant medical benefit. Targacept is dedicated to building health and restoring independence for patients. For more information, please visit www.targacept.com.
Building Health, Restoring Independence®
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
Michelle Linn, 508-362-3087
Source: Targacept, Inc.Copyright Business Wire 2013